IN8bio shares surge 11.72% after-hours on promising DeltEx therapy clinical trial results for glioblastoma.

IN8bio surged 11.72% in after-hours trading following the announcement of promising clinical trial results for its DeltEx™ gamma-delta T cell therapy in glioblastoma. The trials demonstrated improved survival rates compared to standard care, highlighting the therapy’s potential as a breakthrough treatment for the aggressive brain cancer. This positive data, combined with the company’s focus on advancing its pipeline of gamma-delta T cell-based therapies, likely drove investor optimism. While a concurrent corporate presentation and mixed shelf offering filing were disclosed, the immediate price reaction aligns with the clinical milestone, which is a critical near-term catalyst for biotech firms in oncology.